2482992-54-9

2482992-54-9 structure
2482992-54-9 structure
  • Name: HDAC-IN-36
  • Chemical Name: HDAC-IN-36
  • CAS Number: 2482992-54-9
  • Molecular Formula: C29H39N5O5
  • Molecular Weight: 537.65
  • Catalog: Signaling Pathways Apoptosis Apoptosis
  • Create Date: 2022-07-02 13:34:20
  • Modify Date: 2025-08-26 17:41:58
  • HDAC-IN-36 (compound 23 g) is an orally active and potent HDAC (histone deacetylase) inhibitor, with an IC50 of 11.68 nM (HDAC6). HDAC-IN-36 promotes apoptosis, autophagy and suppresses migration. HDAC-IN-36 shows anti-tumor and anti-metastatic activity, and can be used for breast cancer research[1].

Name HDAC-IN-36
Description HDAC-IN-36 (compound 23 g) is an orally active and potent HDAC (histone deacetylase) inhibitor, with an IC50 of 11.68 nM (HDAC6). HDAC-IN-36 promotes apoptosis, autophagy and suppresses migration. HDAC-IN-36 shows anti-tumor and anti-metastatic activity, and can be used for breast cancer research[1].
Related Catalog
Target

HDAC6:11.68 nM (IC50)

HDAC10:13.24 nM (IC50)

HDAC3:79.17 nM (IC50)

HDAC1:86.93 nM (IC50)

HDAC2:97.32 nM (IC50)

HDAC8:378.2 nM (IC50)

HDAC4:>1000 nM (IC50)

HDAC5:>1000 nM (IC50)

HDAC7:>1000 nM (IC50)

HDAC9:>1000 nM (IC50)

HDAC11:>1000 nM (IC50)

In Vitro HDAC-IN-36 (compound 23 g) (0-10, 24 h) exhibits good antiproliferative activity in MDA-MB-231 cells, promotes the acetylation of α-Tubulin and HSP90[1]. HDAC-IN-36 (0-10, 24 h) induces apoptosis in MDA-MB-231 cells in a dose-dependent manner, and mainly induces mitochondrial-dependent apoptosis[1]. HDAC-IN-36 (0-10, 24 h) inhibits MDA-MB-231 cells migration in a dose-dependent manner, increases the expression of E-cadherin and decreases the expression of MMP-2 obviously[1]. HDAC-IN-36 (0-10, 24 h) induces noteworthy autophagy, increases the expression of Beclin1, LC3II and decreases the expression of SQSTM1/p62[1]. Cell Viability Assay Cell Line: MDA-MB-231 cells[1] Concentration: 0, 2.5, 5, 10 μM Incubation Time: 24 h Result: Exhibited good anti-proliferative activity in MDA-MB-231 cells, with IC50 of 1.32 ± 0.13 μM, increased the acetylation level of intracellular proteins, and promoted the acetylation of α-Tubulin and HSP90. Apoptosis Analysis Cell Line: MDA-MB-231 cells[1] Concentration: 0, 2.5, 5, 10 μM Incubation Time: 24 h Result: Induced apoptosis in MDA-MB-231 cells in a dose-dependent manner. Cell Autophagy Assay Cell Line: MDA-MB-231 cells[1] Concentration: 0, 2.5, 5, 10 μM Incubation Time: 24 h Result: Induced noteworthy autophagy with increased aggregation of LC3 puncta. Western Blot Analysis Cell Line: MDA-MB-231 cells[1] Concentration: 0, 2.5, 5, 10 μM Incubation Time: 24 h Result: Mainly induced mitochondrial-dependent apoptosis, up-regulated the expression of Bax and downregulated the expression of Bcl-2, and increased the cleavage of caspase3, caspase8 and caspase9; increased the expression of E-cadherin and decreased the expression of MMP-2 obviously; increased the expression of Beclin1, LC3II and decreased the expression of SQSTM1/p62.
In Vivo HDAC-IN-36 (compound 23 g) (Zebrafish tumor xenograft model; 0-5 μg/mL, 3 days) shows potent anti-tumor and anti-metastatic activity, and improves in vivo anti-tumor efficacy[1]. HDAC-IN-36 (Beagles, 20 mg/kg, Orally, once) shows a significant improvement in pharmacokinetic parameters[1]. Pharmacokinetic Parameters of HDAC-IN-36 in male Beagles[1]. Parameters 23g (20 mg/kg) T1/2 (h) 1.24 ± 0.21 Tmax (h) 0.79 ± 0.33 Cmax (μg/L) 120.36 ± 15.53 AUC0-t (μg/L∗h) 1275.35 ± 70.17 AUC0-∞ (μg/L∗h) 1289.40 ± 88.91 Animal Model: Zebrafish (MDA-MB-231-derived xenograft model, Wild-type AB strain)[1] Dosage: 0, 2.5, 5 μg/mL Administration: 3 days Result: Inhibited tumor formation and migration in a dose-dependent manner, and improved in vivo anti-tumor efficacy. Animal Model: Beagles (female, 8-10 kg, n = 4)[1] Dosage: 20 mg/kg (dissolved 0.5% sodium carboxyl methyl cellulose (CMC-Na) aqueous solution) Administration: Orally, once (Pharmacokinetic Analysis) Result: Showed a significant improvement in pharmacokinetic parameters with T1/2 value of 1.24 h.
References

[1]. Yao D, Li C, Jiang J, et al. Design, synthesis and biological evaluation of novel HDAC inhibitors with improved pharmacokinetic profile in breast cancer. Eur J Med Chem. 2020;205:112648.

Molecular Formula C29H39N5O5
Molecular Weight 537.65
The content on this webpage is sourced from various professional data sources. If you have any questions or concerns regarding the content, please feel free to contact service1@chemsrc.com.